Xeris Biopharma Holdings, Inc.
XERS
$4.40
-$0.485-9.94%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.39% | 12.31% | 26.46% | 22.42% | 33.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.39% | 12.31% | 26.46% | 22.42% | 33.93% |
| Cost of Revenue | 25.20% | 65.75% | 3.11% | 12.26% | 20.33% |
| Gross Profit | 37.48% | 1.39% | 32.25% | 24.36% | 37.12% |
| SG&A Expenses | -9.39% | 20.60% | 6.27% | 14.21% | 14.30% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.52% | 26.16% | 4.20% | 18.10% | 15.81% |
| Operating Income | 179.05% | -162.43% | 48.76% | -7.29% | 28.07% |
| Income Before Tax | 62.48% | -52.17% | 30.52% | -10.92% | -2.70% |
| Income Tax Expenses | 100.00% | -883.43% | 210.96% | -- | 30.18% |
| Earnings from Continuing Operations | 61.81% | -29.12% | 24.38% | -12.75% | -3.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.81% | -29.12% | 24.38% | -12.75% | -3.56% |
| EBIT | 179.05% | -162.43% | 48.76% | -7.29% | 28.07% |
| EBITDA | 259.24% | -445.28% | 59.67% | -9.86% | 36.03% |
| EPS Basic | 64.60% | -19.59% | 30.03% | -10.11% | -1.89% |
| Normalized Basic EPS | 105.75% | -69.85% | 35.40% | -3.86% | 4.04% |
| EPS Diluted | 64.60% | -19.59% | 30.03% | -10.11% | -1.89% |
| Normalized Diluted EPS | 105.75% | -69.85% | 35.40% | -3.86% | 4.04% |
| Average Basic Shares Outstanding | 7.94% | 7.92% | 8.01% | 2.46% | 1.57% |
| Average Diluted Shares Outstanding | 7.94% | 7.92% | 8.01% | 2.46% | 1.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
